@natgeo

National Geographic

Earlier this year, an FDA trial began for a potential glaucoma treatment. Called ER-100 and co-developed by molecular biologist David Sinclair, it aims to return damaged optic nerves to a more youthful state. Theoretically, it could also rewind the clock on any type of cell, making it the latest step in an accelerating race to redefine how our bodies age. D.T. Max explores this research further in our September NGM cover story at the 🔗 in bio.

On the profile · Aug 13, 2026